Allos leverages its proprietary Causal AI platform to bring generic versions of complex drugs to market, addressing an $88B opportunity. Their approach reduces drug development costs by 40% and focuses on securing FDA exclusivity for complex generics. By 2030, hundreds of drugs will go off-patent, and Allos' strategy helps pharmaceutical companies tackle the high costs and risks associated with developing these generics.
At Evolution, we recognize the value of Allos’ innovative use of AI to address critical challenges in the pharmaceutical industry. Their focus on leveraging advanced technology to solve industry-wide issues aligns with our commitment to investing in companies that drive meaningful change and innovation.
Meet The Allos Team
Aditya Varna Iyer, PhD – CEO
Aditya Iyer brings a rich blend of scientific expertise and leadership to Allos. With a DPhil from Oxford and machine learning work at CERN, Aditya drives Allos’ mission to revolutionize complex drug development using AI. His leadership is rooted in combining cutting-edge technology with pharmaceutical innovation, aiming to make complex generic drugs more affordable and accessible.
Isaac To – COO
Isaac To leverages his broad experience in operational strategy, having worked for Walt Disney Imagineering and the Hospital Authority of Hong Kong. His deep understanding of complex systems ensures that Allos operates efficiently while aligning with its AI-driven pharmaceutical goals. Isaac is crucial in streamlining operations as the company scales its mission of reducing drug development costs and timelines.
Balasubramanian (Balu) Krishnamurthy – Chief Pharmaceutical Officer
Balu Krishnamurthy brings decades of pharmaceutical expertise to Allos, having successfully developed and launched over 50 complex generics. Formerly with Aurobindo Pharma, Balu plays a critical role in advancing Allos' pipeline of generic drugs. His deep knowledge in pharmaceutical science complements Allos' technology-driven approach to solving cost and efficacy challenges in drug development.
Ivano Lodato, PhD – Chief Scientist
Ivano Lodato leads scientific innovation at Allos, holding a PhD from the University of Utrecht and previous experience at Fudan University. He spearheads the integration of AI into Allos' drug development process, ensuring the company’s solutions are grounded in cutting-edge scientific research. His work is pivotal in optimizing the accuracy and success rates of clinical trials for complex generics.
To learn more about Allos, visit: https://www.allos.com